



GRANT AGREEMENT

This Grant Agreement ("**Agreement**") is entered into as of march 31st 2017 ("**Effective Date**") by and between Novartis Healthcare A/S, Reg. No. 20575786, a company incorporated under the laws of Denmark, located at Edvard Thomsens Vej 14, DK-2300 Copenhagen S, Denmark ("**Novartis**") and the Danish Molecular Hematologist group, an incorporated under the laws of Denmark, represented by steering committee member Niels Pallisgaard, Patologiafdelingen Region Sjælland, Afsnit Roskilde, Køgevej 7-13, 4000 Roskilde, ("**Grant Recipient**"). Novartis and Grant Recipient may hereinafter be referred to individually as a "**Party**" and collectively as the "**Parties**".

WHEREAS, Grant Recipient has specifically requested Novartis' financial contribution in order to support the Grant Activity (as defined in Exhibit A), through a Grant Request Letter, which is attached hereto as Exhibit B;

WHEREAS, in accordance with the Grant Request Letter mentioned above, Novartis wishes to support the Grant Activity with the Grant Amount (as defined in Exhibit A); and

WHEREAS, Grant Recipient accepts the Grant Amount subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, it is mutually agreed as follows:

1. GRANT BY NOVARTIS

- 1.1 **Grant.** Novartis will provide the Grant Amount as set forth in Exhibit A solely to support Grant Recipient in performing the Grant Activity as set forth in Exhibit A.
- 1.2 **Statement of Purpose.** The Grant Activity is for scientific and/or educational purposes only and will not promote Novartis' products, directly or indirectly. The Grant Amount is not being given in exchange for any explicit or implicit agreement to purchase, prescribe, recommend, influence or provide favorable formulary status for any of Novartis' products. The Grant Amount is based upon a budget provided to Novartis by Grant Recipient reflecting a good faith estimate of the actual cost of the Grant Activity. The Grant Amount has not been determined in a manner that takes into account the volume or value of referrals or business, if any, generated between Novartis and Grant Recipient or any of their respective officers, directors, employees, agents, affiliates, parents or subsidiaries.
- 1.3 **Novartis Responsibility.** Grant Recipient agrees that Novartis' responsibility is solely to provide the Grant Amount. Novartis will not be liable to Grant Recipient or to any other person for the Grant Activity or the use of the Grant Amount (including any claims or losses related thereto). Novartis may terminate this Agreement and require Grant Recipient to return the Grant Amount and take other corrective action if Grant Recipient breaches this Agreement.



2. OBLIGATIONS OF GRANT RECIPIENT

2.1 Use of Grant Amount.

- (a) Grant Recipient shall use the Grant Amount solely for the Grant Activity and shall not use the Grant Amount for any activity that is inconsistent with, or prohibited by any law, rule or regulation. The Grant Recipient undertakes to independently contact Novartis in the event any part of the Grant Amount has not been used for the Grant Activity so that such amount can be refunded to Novartis without undue delay.
- (b) Grant Recipient will comply with (and shall be solely responsible for any failure to comply with) all relevant laws, rules and regulations (including any code of practice or other guidelines generally followed by pharmaceutical companies in the relevant country) in connection with the Grant Activity. Grant Recipient warrants that the Grant Activity is compliant with all such requirements.
- (c) Grant Recipient is solely responsible for the manner in which the Grant Amount is disbursed, recorded and accounted and for all contractual and other relationships with third parties relating to the Grant Activity and the use of the Grant Amount. Any claims for payment from third parties involved in the Grant Activity are the sole responsibility of Grant Recipient and Novartis will not fund any additional amounts for the Grant Activity.

2.2 Objectivity & Balance.

- (a) The Grant Activity will be independent, non-promotional and free from commercial influence or bias.
- (b) If the Grant Activity involves the discussion of Novartis products, or the comparison of Novartis products with other products, that discussion and/or comparison must be objective, balanced, accurate, not misleading or deceptive and in compliance with all applicable laws, rules and regulations. Where appropriate, the Grant Activity will include a discussion of multiple treatment options, and will not focus on a single product.
- (c) Grant Recipient will ensure that any titles or overview information relating to the Grant Activity will fairly and accurately represent the scope of the planned activity.
- (d) If required, Grant Recipient is responsible for selection of presenters, moderators and collaborators for the Grant Activity. Novartis will not control the planning, content, speaker selection or execution of any Grant Activity. If Novartis suggests presenters, moderators or collaborators, Grant Recipient will record the role of Novartis in making the suggestion, seek other sources and make a final selection based on balance and independence.

2.3 Disclosure of Financial Relationships.

- (a) Grant Recipient will: (i) disclose, to all audiences and in all publications relating to the Grant Activity, that Novartis has provided a grant to support the Grant Activity; (ii) acknowledge support from Novartis in brochures, syllabi, and other materials related to the Grant Activity; and (iii)



disclose any other relationships Novartis has with any individual speakers, moderators, collaborators or Grant Recipient which a reasonable and ethical person would expect to be disclosed.

- (b) Novartis may disclose publicly the financial and non-financial support provided to Grant Recipient, including, without limitation, the Grant Recipient's identity, the Grant Amount and purpose of the support.

2.4 Ancillary Activities.

- (a) If the Grant Activity occurs as part of an overall activity that includes commercial activities, such activities will neither influence planning nor interfere with the Grant Activity. No commercial activities will be permitted in the same room as an educational activity, unless (i) this is allowed in the country in which the activity will take place and (ii) only to the extent that such commercial activity does not interfere with the purpose of the Grant Activity.
- (b) The scheduling of meals and/or receptions, if any, in connection with any portion of the Grant Activity is at the sole discretion of Grant Recipient. Meals and/or receptions, if any, will be modest and conducive to the Grant Activity, and the amount of time at the meals or receptions will be clearly subordinate to the overall amount of time.
- (c) Reconciliation of Expenses. At the conclusion of the Grant Activity, Grant Recipient will provide to Novartis a reconciliation of the actual expenses versus estimated expenses and will issue a refund to Novartis for any portion of the Grant Amount not incurred in the implementation of the Grant Activity. In addition, Grant Recipient will retain appropriate records of the Grant Activity and the use of the Grant Amount and will provide copies of the records to Novartis on request to confirm that the Grant Amount has been used in accordance with this Agreement.

3. GENERAL

- 3.1 **Entire Agreement.** This Agreement, together with its Exhibits, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications between the Parties with respect to such subject matter. In the event of any conflict between a substantive provision of this Agreement and any Exhibit hereto, the substantive provisions of this Agreement shall prevail.
- 3.2 **Governing Law and Jurisdiction.** This Agreement shall be governed by and construed under the laws of Denmark, without giving effect to the conflicts of laws provision thereof. Any dispute or claim arising out of or in connection with this Agreement which cannot be settled amicably between the Parties, is to be brought before the Maritime and Commercial Court in Copenhagen or, if this court is not competent, before a competent court of law in the Kingdom of Denmark.
- 3.3 **Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be executed by their duly authorized representatives.



NOVARTIS HEALTHCARE A/S

Signature 1 – Contract Owner

By: Moreno Maria Dolores

Name: Maria Dolores Herman Moreno

Title: Nordic Medical Disease Area Lead

Date: _____

Signature 2 – Business Area Head

By: Tarje Bergdahl

Name: Tarje Bergdahl

Title: Nordic Medical Franchise Head

Date: _____

Danish Molecular Hematology Group

By: Niels Pallisgaard

Name: Niels Pallisgaard

Title: Molekylærbiolog

Date: 04.04.2017



EXHIBIT A

GRANT AMOUNT & GRANT ACTIVITY

Grant Amount: 11.135 DKK

Grant Activity: Supporting meeting in the Danish molecular hematology group.

DANSK MOLEKYLÆRHÆMATOLOGISK GRUPPE
FORÅRSMØDE TORSDAG 6. april 2017
FIRST GRAND HOTEL, ODENSE
Chair: Niels Pallisgaard

PROGRAM:

09:30-10:00	Kaffe
10:00-10:10	Velkommen, næste møde, valg af referent Niels Pallisgaard, Roskilde
10:10-10:50	NGS ved Myeloide neoplasier i Aarhus Anni Aggerholm, Aarhus
10:50-11:30	Tolkning og rapportering af NGS resultater på kliniske prøver Morten Tolstrup Andersen, Rigshospitalet
11:30-12:00	Opfølgning på BCR-ABL1 Nordisk Guidelines Niels Pallisgaard, Roskilde
12:00-13:00	Frokost
13:00-13:15	BCR-ABL1 T315I mutations analyser vha ddPCR Niels Pallisgaard, Roskilde
13:15-14:00	FLT3 mutationer hos AML patienter TBD
14:00-14:30	FLT3 analyser efter patientets udløb Morten Tolstrup Andersen, Rigshospitalet
14:30-15:00	Kaffe
15:00-15:30	ddPCR assay for early detection of JAK2 V617F and CALR type 1 and type 2 mutations in the general population Lasse Kjær, Roskilde
15:30-15:45	Afslutning

Sponsor: Novartis



The Grant amount is payable against the corresponding invoice within sixty (60) days of its receipt and at the end of a calendar month.

The invoice shall include all details (including a Purchase Order Number) as specified in the Purchase Order received by Grant Recipient at the following email address:

nipa@regionsjaelland.dk

The amount is to be paid to the following account:

Bank: Jyske Bank

Reg.: 5067

Account: 3240003

(BIC/Swift code: JYBADKKK, IBAN: DK9550670003240003)

Tax added to payment: *"Konto 8051107000 tilhørende Afdelingsledelsen. Patologiafdelingen Region Sjælland"*.



EXHIBIT B

GRANT REQUEST LETTER

Roskilde, 13. marts 2017

Malene Kjørup
Disease Area Manager
Novartis Healthcare A/S
Edvard Thomsens Vej 14, 3. sal
DK-2300 Copenhagen S
DENMARK
malene.kjorup@novartis.com

Vedr. Dansk Molekylærhæmatologisk Gruppens Forårsmøde 2017

Kære Malene Kjørup

Undertegnede søger hermed Novartis om støtte til at afholde et dagsmøde i Odense for Dansk molekylærhæmatologisk gruppe (program vedhæftet). Der søges støtte til lokaler og forplejning under mødet. Prisen vil være kr. 655 per person, fordelt på lokaleleje: kr. 205,00; morgenforplejning: kr. 105,00; frokost: kr. 220,00; eftermiddagskaffe/kage: kr. 125,00. Jeg forventer 17 deltagere til mødet og der søges derfor om i alt kr. 11.135.

Skulle Novartis vælge at støtte mødet bedes beløbet indbetalt til Sjællands Universitetshospitals konto i Jyske Bank nummer 5067-3 240003 (BIC/Swift code: JYBADKKK, IBAN: DK9550670003240003) med teksten "Konto 8051107000 tilhørende Afdelingsledelsen, Patologifdelingen Region Sjælland".

Venlig hilsen

Niels Palligaard
Molekylærbiolog

Sjællands Universitetshospital
Roskilde
Patologifdelingen
Sjællandsvej 10
4000 Roskilde

Tlf. +45 99 56 61 99
Mobil +45 20 11 17 27
e-mail nipa@regionsjaelland.dk
www.regionsjælland.dk

REGION SJÆLLAND
SJÆLLANDS UNIVERSITETSHOSPITAL



- vi er til for dig